Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8 Gastrointestinal 7 Breast 7 Other hematologic neoplasm 6 Thoracic 4 Other solid neoplasm 3 Head & Neck 3 Dermatologic 3 Tumor-Agnostic 2 Myeloid 1 Lymphoid 1 Gynecologic 1

Conditions

Peritoneal Neoplasms 1

Interventions

Paclitaxel 35 Bevacizumab 31 Carboplatin 29 pembrolizumab 25 Specimen Handling 20 Magnetic Resonance Spectroscopy 18 olaparib 16 Cisplatin 15 liposomal doxorubicin 13 Taxes 12 Immunoglobulin G 11 Gemcitabine 11 Disulfides 11 Topotecan 9 Nivolumab 9 Cyclophosphamide 9 Biopsy 8 fludarabine 7 Doxorubicin 7 mirvetuximab soravtansine 6 niraparib 5 Radiation 5 Oxaliplatin 5 Fulvestrant 5 Fluorouracil 5 trastuzumab deruxtecan 4 durvalumab 4 cediranib 4 Platinum 4 Megestrol Acetate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Standard of Care × Gynecologic × 30 days × Clear all

NCT07001748 2026-05-15

STOPGAP II

Eastern Cooperative Oncology Group

Phase 2/3 Recruiting

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡